Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulin

There have been several epidemiologic studies investigating the association between circulating levels of insulin‐like growth factor I (IGF‐I), insulin‐like growth factor binding protein 3 (IGFBP‐3), and insulin in relation to the risk of prostate carcinoma, with conflicting results. To examine this issue further, the authors conducted a nested case–control study within the Cardiovascular Health Study cohort.

[1]  T. Peters,et al.  Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control study , 2004, International journal of cancer.

[2]  D. Albanes,et al.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.

[3]  W. Aronson,et al.  Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. , 2003, Endocrinology.

[4]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[5]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[6]  L. Bégin,et al.  Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. , 2002, The Journal of urology.

[7]  R. Baxter,et al.  IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. , 2002, Endocrinology.

[8]  Pinchas Cohen,et al.  Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. , 2002, Cancer research.

[9]  M. Poot,et al.  Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[10]  K. Helzlsouer,et al.  Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  S. Chua,et al.  Prostate cancer risk and serum levels of insulin and leptin: a population-based study. , 2001, Journal of the National Cancer Institute.

[12]  T. Fears,et al.  Insulin-like growth factors and prostate cancer: a population-based case-control study in China. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  A. Scorilas,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer , 2022 .

[14]  E. Riboli,et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.

[15]  E. Metter,et al.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  T. Tammela,et al.  Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  M. Pollak.  Insulin-like growth factor physiology and cancer risk. , 2000, European journal of cancer.

[18]  C. Rosen,et al.  Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. , 1999, Clinical chemistry.

[19]  B. Foster,et al.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. , 1999, Cancer research.

[20]  C. Schaefer,et al.  IGF-I and Prostate Cancer , 1998, Science.

[21]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[22]  S. Monti,et al.  Insulin-Like Growth Factor-I and -II in Human Benign Prostatic Hyperplasia: Relationship with Binding Proteins 2 and 3 and Androgens , 1998, Steroids.

[23]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[24]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[25]  E. Barrett-Connor,et al.  Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. , 1997, American journal of epidemiology.

[26]  C. Roberts,et al.  Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. , 1996, Endocrinology.

[27]  G. Rodier,et al.  Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. , 1996, The Journal of clinical endocrinology and metabolism.

[28]  D. Yee,et al.  Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  L H Kuller,et al.  Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. , 1995, Annals of epidemiology.

[30]  M. Cushman,et al.  Laboratory methods and quality assurance in the Cardiovascular Health Study. , 1995, Clinical chemistry.

[31]  D. Peehl,et al.  Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. , 1994, The Journal of clinical endocrinology and metabolism.

[32]  M. Serio,et al.  Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization. , 1994, The Journal of clinical endocrinology and metabolism.

[33]  B. Sente,et al.  Benign prostatic hyperplasia and normal prostate aging: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. , 1993, The Journal of clinical endocrinology and metabolism.

[34]  O. Cussenot,et al.  IGF binding protein-3 secreted by the prostate adenocarcinoma cells (PC-3): differential effect on PC-3 and normal prostate cell growth. , 1993, Growth regulation.

[35]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[36]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[37]  R. Baserga,et al.  Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. , 1993, Cancer research.

[38]  D. Peehl,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. , 1991, The Journal of clinical endocrinology and metabolism.

[39]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[40]  R. Baxter.  Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex. , 1988, The Journal of clinical endocrinology and metabolism.

[41]  L. Chung,et al.  Prostate carcinoma cells that have resided in bone have an upregulated IGF‐I axis , 2004, The Prostate.

[42]  C. Roberts.  IGF-1 and prostate cancer. , 2004, Novartis Foundation symposium.

[43]  Jie Deng,et al.  Insulin resistance and prostate cancer risk. , 2003, Journal of the National Cancer Institute.

[44]  M. Stampfer,et al.  Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[45]  J. Ricort,et al.  Insulin-like Growth Factor-binding Protein-3 Activates a Phosphotyrosine Phosphatase EFFECTS ON THE INSULIN-LIKE GROWTH FACTOR SIGNALING PATHWAY* , 2002 .

[46]  M. Pollak,et al.  Insulin-like growth factor physiology and neoplasia. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[47]  A. Juul,et al.  Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulation , 1999, Journal of clinical laboratory analysis.

[48]  D. Leroith,et al.  Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. , 1997, Endocrinology.

[49]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.